Colorectal LLM Wiki

Browse
Home / Sources / ASCRS Ch52 - Clostridium difficile Infection
Source created 2026-08-25 · updated 2026-08-25
colorectalc-diffinfectious-diseasetextbook

ASCRS Ch52 - Clostridium difficile Infection

Fifty-second chapter of the ASCRS Textbook of Colon and Rectal Surgery, 4th edition (Paquette IM, Stewart DB). Book pages 879–891 (PDF pages 871–883 of raw/ASCRS Textbook 4th Ed.pdf, offset +8 — one higher than the +7 that held through Ch51, confirmed by printed folio; a blank unnumbered page apparently falls between Ch51 and Ch52). A dedicated, much more granular treatment of C. difficile infection (CDI) than the existing wiki content, which was Sabiston-textbook-sourced. Substantially deepens essentially every subsection already on Infectious Colitis and adds several genuinely new ones (nomenclature/genetics, ribotype detail, a second severity-scoring schema, and much more trial-level detail on antibiotic choice and surgical management).

Key concepts (chapter's own summary box)

  • More virulent strains of C. difficile such as ribotype 027 are associated with severe clinical infection.
  • CDI in IBD patients should be treated with vancomycin.
  • CDI is often associated with an exaggerated leukocytosis.
  • Fecal transplant is effective therapy for recurrent CDI.

Epidemiology

CDI now responsible for ≥20% of antibiotic-associated diarrhea cases; incidence continues to rise, and in many hospital settings CDI has become the most common cause of hospital-acquired infection, surpassing MRSA. CDC data: a fourfold increase in CDI from 1993 to 2009, with incidence in patients >65 increasing by over 200%. At least one ribotype (027) has been associated with >15× the production of toxins A and B compared to other strains, plus production of a third toxin (binary toxin) — associated with higher rates of toxic colitis and increased mortality. Falcone found metronidazole monotherapy (HR 2.38) and immunosuppressive treatment (HR 3.11) both associated with recurrent CDI in ribotype-027-positive patients specifically — the chapter advocates for vancomycin as primary treatment over metronidazole when ribotype 027 is identified. Economic burden: a meta-analysis (Nanwa, 1988–2014 studies) found attributable direct costs of $8,911–$30,049 per hospitalization; a second study (McGlone) agreed with these estimates and extrapolated to an annual US economic burden of $496 million (hospital perspective) / $547 million (third-party payer perspective); combining inpatient and outpatient perspectives, the cost to the US healthcare system has been estimated at a staggering $3 billion.

Clinical risk factors

Advanced age: though commonly cited, the literature suggests medical comorbidities rather than age itself may be the more important predisposing factor (young and old CDI patients have similar presentations/comorbidities in several studies). Lee found more severe colitis and more frequent first-line-treatment failure in older (>65) vs. younger patients. Louie's RCT of vancomycin/ fidaxomicin for severe CDI found lower clinical cure rates and higher clinical recurrence for each successive decade of age (comparing patients 18–40 to older cohorts).

Antibiotic treatment: the most consistent, most modifiable risk factor. Almost any antibiotic used over time can be associated with CDI, but clindamycin, fluoroquinolones, carbapenems, and cephalosporins are most commonly implicated. A systematic review found clindamycin and carbapenems most strongly associated. Slimings' review of 13 heterogeneous studies found ORs: second-/third-/ fourth-generation cephalosporins 3.2, clindamycin 2.8, fluoroquinolones 1.6. Antibiotics should be used judiciously and discontinued as soon as possible once CDI is diagnosed; certain bacterial species (Bacteroides, Bifidobacteriae, Lachnospiraceae) seem most prevalent among species conferring colonization resistance. Probiotic use for primary CDI prevention during antibiotic courses is controversial — some meta-analyses suggest a decreased incidence, but arguments against this strategy note that baseline CDI incidence in hospitalized patients >65 on antibiotics without probiotics is already <3%, and excluding higher-than-expected-incidence studies from the meta-analyses much reduces the apparent effect size; heterogeneity of probiotic types/doses/patient populations makes a confident recommendation currently impossible.

Contact with a healthcare facility: hospital-related factors (e.g., increasing bed occupancy) are independently associated with CDI risk, beyond patient-level risk factors, given concentration of at-risk patients and fecal-oral transmission opportunity. Antibiotic stewardship, contact precautions, handwashing (soap preferred over alcohol-based disinfectant specifically for C. diff), disinfection practices, and CDI treatment protocols all reduce incidence — but not all hospitals consistently follow these practices. A New York statewide study (Aquina, 150,878 patients having segmental colectomy or proctectomy) found CDI incidence ranging from 0% to 11.3% among individual surgeons and 0% to 6.8% among hospitals — patient factors explained only 24% of this variation, with ~70% coming from unexplained hospital-level factors — a striking illustration of how much CDI risk is institutional rather than patient-driven.

Immunocompromised states: immune-system compromise (regardless of cause) is associated with CDI development, though it's unclear whether immunosuppression alone is sufficient or whether immunocompromised patients simply also tend to have several of the other classic risk factors (hospitalization, antibiotic use). HIV patients: risk factors include low serum albumin, clindamycin use, prolonged hospital stay, and PPI use; the strongest HIV-specific risk factor is CD4 count ≤50/mm³, with an adjusted OR of 5.2–27.6. Other reported immunocompromised populations at CDI risk: general oncology patients, solid organ transplant recipients, and stem cell transplant recipients — though most of these patients also exhibit the classic risk factors (prolonged hospitalization, antibiotic use) as well.

Inflammatory bowel disease: CDI has been increasing in IBD patients and may be associated with increased morbidity, mortality, and need for surgery; both Crohn's disease and UC patients are at risk, with CDI presentation most often happening during an acute disease exacerbation. Genetic polymorphism evidence: the TNFRSF14 locus has been associated with a sixfold increase in CDI development risk in one study. Clinical risk factors specific to IBD-associated CDI: low serum albumin, hemoglobin <9 g/dL, active colitis, biologic use, and antibiotic use. Relationship between active colitis, steroid use, and antibiotic use with CDI is consistently shown; some studies fail to show an association between biologic medication use and CDI specifically. Testing for CDI is recommended in IBD patients with severe colitis. Though evidence supports early vancomycin administration to treat the CDI, these patients need close clinical monitoring, as at least one study estimated a sixfold increase in the need for colectomy in this setting.

Perioperative prophylactic antibiotics and mechanical bowel preparation: for decades, elective colectomy patients typically received combined mechanical + oral antibiotic bowel preparation to minimize infectious complications. Bowel prep fell out of favor for years, but recent studies have highlighted improved outcomes (decreased SSI and anastomotic leak) with mechanical bowel prep plus oral antibiotics; some data suggests oral antibiotics alone (without mechanical prep) may still decrease SSI incidence following colectomy. It's possible that beneficial microbiome changes underlie these improved surgical outcomes; however, there are concerns that microbiome changes could also make a patient more susceptible to pathogens like C. difficile. Literature on this specific concern is sparse — one study (Morris) found 9.5% of CDI patients had only preoperative oral-antibiotic utilization as an identifiable risk factor, which likely does not outweigh the SSI/anastomotic-leak benefits of these agents. The comparative data described above actually showed patients receiving mechanical bowel preparation with oral antibiotics had a lower incidence of postoperative CDI. The most important factor in reducing CDI risk is likely appropriate adherence to guidelines and cessation of perioperative antibiotics as soon as feasible — one study (Balch) found patients receiving perioperative antibiotics for >24 hours had a 6.7-fold increase in CDI incidence compared to those receiving ≤24 hours of therapy.

Proton pump inhibitors: a clinical association exists between PPI use and CDI, though causation is difficult to establish given the many other confounding risk factors typically also present. One recent in vitro study (Stewart) found that omeprazole stimulated C. difficile toxin production in both acidic and basic environments — a plausible mechanism. Four recent meta-analyses (combining data on >300,000 patients) suggest an OR of 1.6–1.7 for CDI development in hospitalized patients on PPIs, though these analyses were limited by significant data heterogeneity and (in two of the four) noted publication bias. Randomized data with adequate control of other clinical risk factors is lacking, and current evidence does not support global discontinuation of PPIs in hospitalized patients — though physicians should be judicious about starting PPIs for questionable indications ("prophylaxis").

Nomenclature and genetics of C. difficile infection

The proper genus designation is Clostridioides, not Clostridium — changed in 2016 based on phylogenetic studies restricting genus Clostridium to C. butyricum and similarly related species. Despite the genus reassignment, the common name "C. difficile" has continued in clinical use to avoid confusion/re-labeling costs. CDI is mediated by bacterial envenomation: the pathogenicity locus (PaLoc), a 19.6 kb genetic region, contains the genes for toxins A (tcdA) and B (tcdB) plus regulatory genes; these toxin genes are of bacteriophage (viral) origin, retained as bacterial genes over successive replicative generations under selective pressure. Toxins A (308 kDa) and B (269 kDa) are large clostridial toxins that initiate monoglucosylation of intracellular Rho GTPases, causing cytoskeletal depolymerization and colonocyte cytopathy. Some (not all) strains also produce binary toxin (CDT), encoded outside the PaLoc — has an ADP-ribosyltransferase function requiring internalization by colonocytes, alters the apical colonocyte membrane to increase surface area up to fivefold and promote adherence of both the organism and its toxins. Binary toxin is present in up to 6% of all C. difficile isolates. Toxins A and B are present in virtually all symptomatic infections.

Ribotype and clinical severity

Ribotyping (a restriction-enzyme technique characterizing the bacterial ribosomal intergenic spacer region) is the most common way to characterize dominant C. difficile strains. Ribotype 027 is the most frequently identified strain associated with severe CDI and the most frequently encountered strain among patients admitted from long-term healthcare facilities (adjusted OR 4.87 vs. patients admitted from a private residence) — likely reflecting a selective colonization/carriage advantage. Comparative genomics show ribotype 027 has >200 genes not found in other strains, many plausibly related to virulence. Other ribotypes such as 078 represent potentially virulent strains with a zoonotic (human-animal) link, creating an important interaction between humans, animals, and the environment in the emergence of new virulent strains.

Diagnosis of C. difficile infection

CDI (a disease capable of both toxin-mediated and toxin-independent colitis) should be kept distinct from carrier states (positive stool test without symptoms) — not uncommon: one study of 262 geriatric patients without diarrhea found 43 (16.4%) toxin-B-positive by PCR, of whom 7 (16.3%) eventually developed symptomatic CDI — carrier states are more common with frequent healthcare contact and predispose to subsequent symptomatic infection. Diarrhea (typically non-bloody) is the primary symptom; other findings scale with severity (abdominal distention/pain, tachycardia, hypotension in fulminant disease; localized/generalized peritonitis can develop). CT findings include colonic wall thickening and pericolic fat stranding; pneumoperitoneum and portal venous gas are rarer, more severe findings typically seen with fulminant infection/non-viable colon from severe mesenteric vasoconstriction.

Testing evolution: bacterial culture (historically the confirmatory test, difficult/slow) → cell culture cytotoxicity neutralization assay (CCCNA, the historical "gold standard," but slow — 24–48h — and now largely replaced by more sensitive tests, sensitivity as low as 65%) → toxigenic culture (also largely outdated; multi-step, technically demanding). Current approach: glutamate dehydrogenase (GDH) immunoassay — a conserved metabolic enzyme present in both toxigenic and non-toxigenic C. difficile, so GDH alone lacks specificity but is an excellent high-sensitivity (80–100%) screening test with strong negative predictive value, limited cost, and rapid turnaround — must be followed by a confirmatory toxin enzyme immunoassay (EIA) if positive. Nucleic acid amplification tests (NAATs, PCR-based) are more sensitive than EIA or GDH-EIA combinations, though cost 2–3× more than GDH-EIA and may have longer turnaround. Many hospitals use an algorithmic approach: GDH screen first (negative ends the algorithm); positive GDH → confirmatory toxin EIA; GDH-positive/EIA-negative stool → NAAT. Routine re-testing with NAATs to confirm CDI resolution is not recommended, given bacterial DNA can persist up to 30 days in patients who no longer have active CDI.

Clinical measures of severity

No severity scoring system has emerged as clearly superior; the two most commonly used:

  • IDSA (2017): non-severe = WBC <15,000/mL and serum creatinine <1.5 mg/dL; severe = WBC ≥15,000/ mL and/or serum creatinine ≥1.5 mg/dL; fulminant = evidence of cardiovascular shock, ileus, or megacolon.
  • ACG: severe = WBC ≥15,000/mL and serum albumin <3 g/dL; fulminant = any ICU admission requirement, or temperature ≥38.5°C, ileus, significant abdominal distention, altered mental status, WBC >35,000/mL or <2,000/mL, serum lactate >2.2 mmol/L, or evidence of organ dysfunction.

Antibiotic therapy for CDI

For >20 years, metronidazole and vancomycin were the two principal CDI antibiotics. Zar's 2007 randomized, prospective, double-blind, placebo-controlled trial (150 patients, mild or severe CDI, metronidazole 250mg QID vs. vancomycin 125mg QID) found no significant cure-rate difference in mild disease, but for severe disease vancomycin had a significantly higher cure rate (97% vs. 76%, p=0.02). Retrospective data focused on mild disease also suggests vancomycin superiority, with one study finding metronidazole an independent risk factor for treatment failure even in mild disease. Current IDSA recommendations: oral metronidazole should be restricted to an initial episode of non-severe CDI when other therapies are contraindicated/unavailable, and treatment limited to one course given case reports of neurotoxicity with prolonged/repeated metronidazole use. Vancomycin has emerged as the recommended drug for both mild and severe CDI.

Fidaxomicin: a macrocyclic drug with a narrow antibiotic spectrum via inhibition of the RNA polymerase sigma subunit. First Phase III study (629 subjects) demonstrated non-inferiority to vancomycin for clinical cure, with lower recurrence rates, though only for non-NAP-1 (non-027) strains. The EXTEND study (364 patients, vancomycin vs. extended-pulse fidaxomicin) found fidaxomicin associated with an 11% improvement in 30-day clinical cure vs. vancomycin, with no difference in treatment-related adverse events. A Cochrane review (22 studies, 3,215 patients total) concluded moderate-quality evidence that vancomycin is superior to metronidazole, and fidaxomicin is superior to vancomycin — with the caveat that the effectiveness differences between these antibiotics were "not too large," and metronidazole's far lower cost is a genuine advantage.

Recommended regimens: first episode of non-severe CDI — vancomycin 125mg PO q6h or fidaxomicin 200mg q12h, either for 10 days. Fulminant CDI — oral vancomycin 500mg q6h (the most effective treatment); ileus may reduce oral/enteral drug delivery efficacy/safety, so vancomycin can be administered as a retention enema (500mg in 100cc normal saline q6h) though supporting data quality/strength is weak; IDSA also recommends adding parenteral metronidazole 500mg q8h in fulminant CDI, given the risks of a limited metronidazole course are small relative to the risk of progressively worsening CDI.

Surgery for CDI

Estimated incidence of CDI patients requiring surgery: as high as 10%. Deciding whether a patient has received maximal medical therapy (with surgery as the only remaining option), and identifying which patients meet criteria but aren't good surgical candidates, is inherently difficult — multiple series indicate only a small percentage of fulminant CDI patients undergo surgery, suggesting most CDI patients don't develop medically refractory disease severe enough to warrant it. Patients with severe, complicated/fulminant CDI should be managed multidisciplinarily; surgical consultation is recommended as soon as this severity is recognized, to allow surgical intervention at the earliest appropriate time. CDI is frequently associated with organ failure, including hematologic failure characterized by an exaggerated leukocytosis (often >30,000 cells/mm) — euvolemia should be maintained when assessing sepsis severity, with greater emphasis on trending organ function than absolute lab cutoffs. De-escalating/discontinuing non-C.-difficile-targeted antibiotics is important (though the supporting data is limited) — CDI outcomes are worse when the inciting antibiotics are continued during CDI treatment.

Extent of resection: the largest body of evidence supports total abdominal colectomy with end ileostomy; partial colectomy has extremely limited utility given a significantly higher reoperation rate due to postoperative fulminant CDI. Diverting loop ileostomy (with on-table colonic lavage, antegrade vancomycin flushes) is a colon-sparing alternative with growing evidentiary support:

  • Neal 2011 (landmark first modern description, 42 fulminant-CDI patients treated with diversion vs. a historical colectomy/end-ileostomy control group): diversion cohort had significantly lower postoperative mortality (19% vs. 50%) and shorter length of surgery; 83% of diversion patients had their surgery completed laparoscopically. Diversion also demonstrated a decrease in colonic inflammation on biopsy after the procedure; in collagenous colitis specifically, collagen-band size has also been shown to decrease after diversion (unrelated finding, cited for mechanistic interest).
  • EAST Multi-Center Trials Committee study (2017, 10 centers): no statistically significant differences between total colectomy and diversion cohorts in preoperative vital signs, WBC, lactate, INR, APACHE scores, or postoperative complication rate/pneumonia/acute renal failure/ARDS/ reoperation/ICU days/hospital LOS. Unadjusted mortality was comparable (23.8% diversion vs. 33.8% colectomy, p=0.44), but after inverse-probability-of-treatment-weighting (propensity score analysis), mortality was significantly lower with diversion (17.7% vs. 39.7%, p=0.002). A significant limitation: inability to identify the actual selection criteria used for choosing the surgical approach at each center, which affects interpretation of the measured outcomes.
  • 2019 Nationwide Inpatient Sample study (2,408 patients, 2011–2015): diversion-with-loop- ileostomy use increased from 11% (2011) to 25% (2015) of CDI surgical patients, suggesting more surgeons are adopting diversion as their surgery of choice for fulminant CDI. In-hospital mortality did not significantly differ between diversion and colectomy cohorts in this dataset, though important severity-of-disease details were not available.

An open question raised by a letter to the editor responding to the EAST study: several unanswered questions remain regarding this newer surgery, and the particular infecting C. difficile strain (frequently missing information from the surgical CDI literature) may influence postoperative outcomes — especially when a diverting stoma is created and an infected colon is left in situ. Summary recommendation: total abdominal colectomy with end ileostomy remains the largest evidence base; loop ileostomy has enough data at this juncture to be an acceptable alternative, though several questions about the newer procedure remain unanswered.

Fecal microbiota transplant (FMT)

Now more readily available for inpatient use (commercially screened/prepared stool, liquid endoscopic/ nasogastric or oral capsule forms) than in earlier eras when providers had to collect/screen/prepare donor stool themselves. FMT is extremely effective for treating recurrent CDI, with cure rates >80% routinely described. FMT for fulminant CDI has the least exploration of all FMT applications, though the few available studies are promising; one challenge specific to fulminant-CDI FMT is disease recurrence and a measurable recurrence-related mortality — incorporating vancomycin alongside FMT appears important for ensuring reliable cure rates in this setting. FMT is no longer an experimental therapeutic for outpatients or inpatients with CDI; its cure rates for recurrent CDI are superior to conventional antibiotics, leading some to question whether FMT should be the first intervention for recurrence rather than a later resort. FMT does not currently represent first-line therapy for a primary episode of CDI. Use of inpatient FMT for CDI has increased in recent years, though most CDI cases are still treated with conventional antibiotics; insufficient data currently exists to recommend routine use of FMT for fulminant CDI specifically, though the limited small-series data suggesting safety/efficacy is encouraging.

Open items / gaps

  • All content above is textbook-level/secondary. The chapter is unusually trial-rich for a survey chapter, however — several named studies stand out as worth independently ingesting: Zar 2007 (vancomycin vs. metronidazole RCT), Neal 2011 (diverting loop ileostomy landmark study), the EAST 2017 multicenter study (colectomy vs. diversion, propensity-weighted mortality benefit for diversion), the EXTEND trial (fidaxomicin vs. vancomycin), and the 22-study/3,215-patient Cochrane review. Flagged in Research Priorities.md.
  • 127 references total; only the load-bearing ones above are flagged — the rest (epidemiology, case reports, mechanistic/microbiology studies) are treated as background.